No profile data available.
Chemomab Therapeutics Ltd. (CMMB) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Tel Aviv-Yafo, Israel.
It reported revenue of $0 for fiscal year 2025, and net income of -$9.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $10.11 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.
Chemomab Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$10.11 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Precision BioSciences, Inc. (DTIL), Aligos Therapeutics, Inc. (ALGS), Hepion Pharmaceuticals, Inc. (HEPA), MetaVia Inc. (MTVA).